Drugs / Parecoxib
Parecoxib
also known as
parecoxib sodium · Dynastat · Brand name: Dynastat · Intravenous parecoxib ("Dynastat" Pfizer) · Parecoxib sodium salt · Parestat · Rayzon · SC-69124 · +2 more
Small molecule targets PTGS2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Dynastat | — | 2002-03-22 | europa.eu ↗ |
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05442411 | Mar 2021 → Mar 2022 | — | Universiti Sains Malaysia | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06579274 | Jan 2025 → Jan 2027 expected | — | St. Anne's University Hospital Brno, Czech Republic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06623513 | Oct 2024 → Sep 2026 overdue | acute pancreatitis | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02185924 | Jan 2009 → Sep 2011 | — | Asklepieion Voulas General Hospital | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT06315920 | May 2026 → May 2028 expected | sickle cell disease | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03059238 | Sep 2016 → Mar 2019 | liver cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02749409 | Aug 2016 → Jul 2018 | — | Chang Gung Memorial Hospital | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03480165 | Jun 2016 → Sep 2017 | — | Universiti Sains Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT00143169 | Sep 2004 → Jun 2005 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00651300 | Apr 2003 → Mar 2004 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00139607 | Sep 2002 → Jan 2005 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00139646 | Apr 2002 → Apr 2004 | — | Pfizer | Terminated | No outcome recorded |
| Phase 417 trials · 1 met primary | ||||||
| Phase 4 | NCT07675473 | Jun 2026 → Jun 2028 expected | pulmonary coin lesion | Long Jiang | Recruiting | No outcome recorded |
| Phase 4 | NCT07154446 | Oct 2025 → Aug 2026 overdue | — | University of Malaya | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06140238 | Sep 2023 → Apr 2024 | — | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 4 | NCT05924412 | Jul 2023 → Sep 2024 | nephropathy, chronic tubulointerstitial, osteoarthritis, knee | University of Chile | Completed | No outcome recorded |
| Phase 4 | NCT05150431 | Dec 2021 → May 2022 | chronic pain syndrome | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04314505 | Mar → Jun 2020 | — | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT04034836 | Oct 2019 → Dec 2021 | neuropathy, painful | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02729935 | Mar → May 2016 | — | University Tunis El Manar | Completed | No outcome recorded |
| Phase 4 | NCT02198924 | Dec 2014 → Nov 2016 | — | Peking Union Medical College Hospital | Completed | Met primary |
| Phase 4 | NCT02272660 | Oct 2014 → Aug 2015 | neuropathy, painful | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02204878 | Jul 2014 → Aug 2015 | liver hemangioma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01930318 | Aug 2013 → Aug 2015 | digestive system cancer | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 4 | NCT01859585 | Mar 2011 → Jan 2013 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT01186159 | Nov 2010 → Jun 2011 | — | Xianwei Zhang | Completed | No outcome recorded |
| Phase 4 | NCT01221025 | Sep 2010 → Dec 2011 | delirium | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT00660855 | Jun → Jul 2004 | — | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00435747 | — | neuropathy, painful | Pfizer | Withdrawn | No outcome recorded |
| Phase not applicable7 trials · 1 met primary | ||||||
| — | NCT06834425 | Feb → Dec 2025 overdue | tendinitis | Taipei Medical University WanFang Hospital | Active not recruiting | No outcome recorded |
| — | NCT05757388 | Mar → May 2023 | — | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT04611685 | Oct 2020 → Oct 2021 | pituitary gland adenoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04847024 | Jul → Sep 2019 | — | Saint Thomas Hospital, Panama | Completed | No outcome recorded |
| — | NCT02408146 | Jan 2014 → Jul 2015 | neuropathy, painful | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| — | NCT01393925 | Jul → Nov 2011 | — | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| — | NCT01566669 | Jun 2009 → May 2010 | benign female reproductive system neoplasm | Liu Weifeng | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT01523379 | — | complex regional pain syndrome type 2 | Ruhr University of Bochum | No longer available | No outcome recorded |
| Comparator or background therapy26 trials | ||||||
| Phase 2 | NCT03915561 Comparator | Mar 2019 → Mar 2020 | pharyngitis | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01288924 Comparator | Feb 2011 → Oct 2015 | — | Chiang Mai University | Completed | No outcome recorded |
| Phase 3 | NCT07414706 Background | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT00636064 Comparator | Jan 2003 → Jan 2004 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT03704623 Comparator | May 2019 → Aug 2020 | ureterolithiasis | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT03135795 Background | Feb → May 2017 | — | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 4 | NCT02569905 Comparator | Apr 2014 → Apr 2015 | — | Guangxi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01843010 Comparator | May → Nov 2013 | — | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT01526525 Comparator | Jul 2009 → Sep 2011 | neuropathy, painful | G.Gennimatas General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00785863 Comparator | Dec 2008 → Apr 2009 | — | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00553605 Comparator | Jun 2007 → Jun 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00346268 Comparator | Dec 2006 → Sep 2010 | — | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00455117 Comparator | Sep 2006 → Dec 2008 | — | Melbourne Health | Completed | No outcome recorded |
| Phase 4 | NCT01361789 Comparator | Jan 2004 → Dec 2009 | — | Asker & Baerum Hospital | Completed | No outcome recorded |
| — | NCT07116304 Comparator | Aug 2025 → Dec 2026 expected | — | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| — | NCT06721988 Background | Jan 2025 → Dec 2026 expected | chronic pain syndrome | Ailin Luo | Not yet recruiting | No outcome recorded |
| — | NCT06304181 Comparator | Mar → Aug 2024 | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Unknown | No outcome recorded |
| — | NCT07604376 Background | Mar 2024 → Jul 2026 overdue | — | Matild Keresztes | Recruiting | No outcome recorded |
| — | NCT07139691 Comparator | Jan 2024 → Jul 2026 overdue | — | Matild Keresztes | Active not recruiting | No outcome recorded |
| — | NCT07568938 Comparator | Jan 2024 → Feb 2027 expected | obesity disorder, substance-related disorder | G.Gennimatas General Hospital | Recruiting | No outcome recorded |
| — | NCT07337135 Background | Oct 2023 → Apr 2024 | morbid obesity | Hospital dos Lusíadas | Completed | No outcome recorded |
| — | NCT06420388 Background | May 2023 → Jul 2024 | — | E-DA Hospital | Unknown | No outcome recorded |
| — | NCT05681429 Background | Jan 2023 → Jan 2024 | — | University of Malaya | Completed | No outcome recorded |
| — | NCT03823846 Comparator | Nov 2017 → Aug 2020 | anaplastic cancer, neuropathy, painful | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT01541137 Comparator | Mar 2004 → Sep 2008 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT00763997 Comparator | Feb → Dec 2004 | platelet aggregation, spontaneous | Ruhr University of Bochum | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parecoxib | “This is a phase III, multicenter, open label, pilot to evaluate the analgesic efficacy and safety of parecoxib 40 mg IV in the treatment of the pain following hemicolectomy in...” NCT00139607 ↗58“The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV.” NCT07139691 ↗ “40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión” NCT05924412 ↗ “a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision.” NCT04314505 ↗ “Postoperative analgesia includes paracetamol + ketorolac/parecoxib + metamizole,” NCT07337135 ↗ “Group B was injected IV parecoxib 40mg during the closure of the scalp.” NCT05442411 ↗ “Regular Tramadol, Metamizol, +/- Ibuprofen/Dexketorpofen/Parecoxib” NCT07604376 ↗ “Peritendinous NSAID (parecoxib) injection” NCT06834425 ↗ “Nefopam (Acupan) 20 mg; Parecoxib 40 mg” NCT07414706 ↗ “Parecoxib (iv.) for once” NCT04611685 ↗ “Dynastat (Parecoxib)” NCT06420388 ↗ |
| Known as | Brand name: Dynastat | “Brand name: Dynastat” NCT01221025 ↗ |
| Known as | Dynastat | “Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation.” NCT03915561 ↗4“40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.” NCT01361789 ↗ “Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration.” NCT06579274 ↗ “Dynastat (Parecoxib)” NCT06420388 ↗ |
| Known as | Intravenous parecoxib ("Dynastat" Pfizer) | “Intravenous parecoxib ("Dynastat" Pfizer)” NCT00455117 ↗ |
| Known as | parecoxib sodium | “Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation.” NCT03915561 ↗5“Participants will receive 0.1ml/kg oxycodone (1mg/ml) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision.” NCT06721988 ↗ “Parecoxib sodium is an injectable prodrug of the cyclooxygenase-2-specific inhibitor valdecoxib that has exhibited analgesic activity in previous trials.” PMID 11589257 ↗ Sep 2001 |
| Known as | Parecoxib sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206690 ↗ |
| Known as | Parestat | “generic parecoxib (Parestat)” NCT07154446 ↗ |
| Known as | Rayzon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206690 ↗ |
| Known as | SC-69124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206690 ↗ |
| Known as | SC-69124A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206690 ↗ |
| Known as | Xapit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206690 ↗ |
| Action | Inhibit | “Parecoxib is an injectable form of NSAID that works through inhibiting cyclo-oxygenase type-2 (COX-2).” NCT00455117 ↗1“Cyclooxygenase-2 inhibitor” CHEMBL1206690 ↗ |
| Modality | Small molecule | “Parecoxib is an injectable form of NSAID” NCT00455117 ↗ |
| Route | Intravenous | “parecoxib 40 mg IV” NCT00139607 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL1206690 ↗ |